COPD, COPD Exacerbation
Conditions
Keywords
microbiota, pulmonary rehabilitation
Brief summary
PRIME goal is to early detect and treat acute exacerbations of chronic obstructive pulmonary disease (AECOPD). This is important since COPD accelerates aging and represents major burden worldwide and in Portugal, mainly due to its frequent AECOPD. Pulmonary rehabilitation (PR) is an effective strategy of its management but it is scarce. When AECOPD are early detected and treated, it optimizes patients' outcomes and reduces the burden of COPD, especially if PR is used. However, up to date, there is no model to predict AECOPD for clinical practice. The lung microbiota shows promise to overcome this barrier and inform on COPD trajectory and will be investigated. In addition, despite of most AECOPD being managed in the community, PR is mainly available in hospitals and less than 1% of patients are having access. Thus, community-based PR will be implemented and a clinical decision tool developed for prioritizing who will most benefit from PR, enhancing evidence-based access to PR.
Detailed description
PRIME aims to address these two gaps, establishing the role of microbiota and clinical data in predicting AECOPD and increasing the evidence on PR in AECOPD through the translation of PR guidelines to the community. Specifically, it aims to: * Explore the longitudinal changes in microbiota and clinical data between stable and exacerbations periods; * Establish the feasibility and short- and long-term effects of community-based PR for AECOPD; * Define the characteristics of patients who most benefit from community-based PR. 156 patients with COPD will be followed monthly for a year and their lung microbiota and clinical data will be analysed. Community-based PR will be delivered to 56 patients. Data will be collected before, at 3 weeks, after PR and at 6 months to assess the feasibility and effects of PR. A clinical decision-making tool (CDMT) to prioritise patients with AECOPD for PR will be developed. The experienced multidisciplinary team will ensure the following novel results: * a clinical and lung microbiota profile of patients with COPD; * a model of AECOPD prediction; * recommendations for community-based PR in AECOPD; * a CDMT to prioritise patients with AECOPD for PR. PRIME will contribute to optimise outcomes, improve AECOPD healthcare services and reduce the burden with COPD.
Interventions
OTHERPulmonary rehabilitation
Pulmonary rehabilitation will be provided to patients presenting an acute exacerbation. The intervention will be composed of exercise training, education and psychosocial support.
Sponsors
Aveiro University
Study design
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
156 patients with COPD will be followed monthly for a year and their lung microbiota and clinical data will be analysed. Community-based PR will be delivered to 56 patients. Data will be collected before, at 3 weeks, after PR and at 6 months to assess the feasibility and effects of PR.
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients are eligible if adults (≥18anos) and present a diagnose of chronic obstructive pulmonary disease (COPD).
Exclusion criteria
* Patients will be excluded if they had an acute cardiovascular event on the previous month or if they have a significant cardiac, immune, musculoskeletal or neurological impairment, or any other that doesn't allow them to perform tests.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in exercise tolerance | Up to 6 months | exercise tolerance in a walking field test |
| Change in lung microbiota | Up to 6 months | lung microbiota from saliva samples |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in resting dyspnoea | Up to 6 months | Resting dyspnoea measured with the modified British medical research council dyspnoea questionnaire, that ranges from 0 to 4, and is related to dyspnoea during activities of daily living. Higher scores demonstrate a higher functional impairment due to dyspnoea. |
| Change in self-efficacy | Up to 6 months | self-efficacy measured with the pulmonary rehabilitation adapted index of self-efficacy tool |
| Change in physical activity | Up to 6 months | Physical activity levels measured with the brief physical activity assessment tool |
| Change in lung function | Up to 6 months | Lung function will be assessed through spirometry to define the airflow limitation (FEV1pp). |
| Change in muscle strength | Up to 6 months | Upper and lower limb muscle strength |
| Change in frequency of exacerbations | Up to 6 months | Number of exacerbations on previous year |
| Change in hospitalizations | Up to 6 months | Number of hospitalizations on previous year |
| Dyspnoea during exercise | Up to 6 months | Dyspnoea experienced during exercise, monitored with the modified Borg dyspnoea scale, that ranges from 0 to 10, where 0 represents no dyspnoea and 10 the worst imaginable dyspnoea. |
| Fatigue during exercise | Up to 6 months | Fatigue experienced during exercise, monitored with the modified Borg dyspnoea scale, that ranges from 0 to 10, where 0 represents no fatigue and 10 the worst fatigue the patient can imagine. |
| Change in emergency department visits | Up to 6 months | Number of emergency visits on the previous year |
| Change in health related Quality of life | Up to 6 months | Measured with the St. George's Respiratory Questionnaire, that measures health related quality of life. It will be used the total score. Scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status. |
Countries
Portugal
Contacts
Primary ContactAlda Marques, PhD
Outcome results
None listed